---
title: 2. Class members
---

import Expander from '../../../src/components/Expander'



<table>
 <tr>
  <th>
   <p>
    Opioid (or opioid combination)
   </p>
  </th>
  <th>
   <p>
    Oral formulations
   </p>
  </th>
  <th>
   <p>
    Other formulations
   </p>
  </th>
 </tr>
 <tr>
  <td>
   <p>
    Alfentanil
   </p>
  </td>
  <td>
  </td>
  <td>
   <p>
    Injection
   </p>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    Buprenorphine
   </p>
  </td>
  <td>
   <p>
    Sublingual tablets
   </p>
  </td>
  <td nowrap="nowrap">
   <p>
    Injection
    <br/>
    Transdermal patches
   </p>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    Buprenorphine + naloxone
   </p>
  </td>
  <td>
   <p>
    Sublingual tablets
   </p>
  </td>
  <td>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    Codeine
   </p>
  </td>
  <td>
   <p>
    Tablets
    <br/>
    Syrup
   </p>
  </td>
  <td>
   <p>
    Injection
   </p>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    Codeine + aspirin (co-codaprin)
   </p>
  </td>
  <td>
   <p>
    Dispersible tablets
   </p>
  </td>
  <td>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    Codeine + paracetamol (co-codamol)
   </p>
  </td>
  <td>
   <p>
    Tablets
    <br/>
    Effervescent tablets
    <br/>
    Capsules
   </p>
  </td>
  <td>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    Diamorphine
   </p>
  </td>
  <td>
   <p>
    Tablets
   </p>
  </td>
  <td>
   <p>
    Injection
   </p>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    Dihydrocodeine
   </p>
  </td>
  <td nowrap="nowrap">
   <p>
    Tablets
    <br/>
    Modified-release tablets
    <br/>
    Oral solution
   </p>
  </td>
  <td>
   <p>
    Injection
   </p>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    Dihydrocodeine + paracetamol (including co-dydramol)
   </p>
  </td>
  <td>
   <p>
    Tablets
   </p>
  </td>
  <td>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    Dipipanone + cyclizine
   </p>
  </td>
  <td>
   <p>
    Tablets
   </p>
  </td>
  <td>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    Fentanyl
   </p>
  </td>
  <td>
   <p>
    Buccal tablets
    <br/>
    Sublingual tablets
    <br/>
    Lozenges
   </p>
  </td>
  <td>
   <p>
    Injection
    <br/>
    Nasal spray
    <br/>
    Transdermal patches
   </p>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    Hydromorphone
   </p>
  </td>
  <td>
   <p>
    Capsules
    <br/>
    Modified-release capsules
   </p>
  </td>
  <td>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    Meptazinol
   </p>
  </td>
  <td>
   <p>
    Tablets
   </p>
  </td>
  <td>
   <p>
    Injection
   </p>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    Methadone
   </p>
  </td>
  <td>
   <p>
    Tablets
    <br/>
    Oral solution
   </p>
  </td>
  <td>
   <p>
    Injection
   </p>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    Morphine
   </p>
  </td>
  <td nowrap="nowrap">
   <p>
    Tablets
    <br/>
    Modified-release tablets
    <br/>
    Modified-release capsules
    <br/>
    Oral solution
    <br/>
    Modified-release suspension
   </p>
  </td>
  <td>
   <p>
    Injection
    <br/>
    Suppositories
   </p>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    Morphine + cyclizine
   </p>
  </td>
  <td>
  </td>
  <td>
   <p>
    Injection
   </p>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    Oxycodone
   </p>
  </td>
  <td>
   <p>
    Modified-release tablets
    <br/>
    Capsules
    <br/>
    Oral solution
   </p>
  </td>
  <td>
   <p>
    Injection
   </p>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    Oxycodone + naloxone
   </p>
  </td>
  <td>
   <p>
    Tablets
   </p>
  </td>
  <td>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    Papaveretum
   </p>
  </td>
  <td>
  </td>
  <td>
   <p>
    Injection
   </p>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    Papaveretum + hyoscine hydrobromide
   </p>
  </td>
  <td>
  </td>
  <td>
   <p>
    Injection
   </p>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    Pentazocine
   </p>
  </td>
  <td>
   <p>
    Tablets
    <br/>
    Capsules
   </p>
  </td>
  <td>
   <p>
    Injection
   </p>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    Pethidine
   </p>
  </td>
  <td>
   <p>
    Tablets
   </p>
  </td>
  <td>
   <p>
    Injection
   </p>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    Pethidine + promethazine
   </p>
  </td>
  <td>
  </td>
  <td>
   <p>
    Injection
   </p>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    Remifentanil
   </p>
  </td>
  <td>
  </td>
  <td>
   <p>
    Injection
   </p>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    Tapentadol
   </p>
  </td>
  <td>
   <p>
    Tablets
    <br/>
    Modified-release tablets
   </p>
  </td>
  <td>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    Tramadol
   </p>
  </td>
  <td nowrap="nowrap">
   <p>
    Capsules
    <br/>
    Orodispersible tablets
    <br/>
    Oral drops
    <br/>
    Soluble tablets
    <br/>
    Modified-release tablets
    <br/>
    Modified-release capsules
   </p>
  </td>
  <td>
   <p>
    Injection
   </p>
  </td>
 </tr>
 <tr>
  <td>
   <p>
    Tramadol + paracetamol
   </p>
  </td>
  <td>
   <p>
    Tablets
    <br/>
    Effervescent tablets
   </p>
  </td>
  <td>
  </td>
 </tr>
</table>


**Did you know …**

In England, more than one in every ten primary care prescriptions for opioids is for transdermal patches?

Buprenorphine and fentanyl transdermal patches are not suitable for acute pain—they should be used for chronic pain only.

**Activity 1**

**Some formulations of opioid medicines include an opioid antagonist[^1]. Which antagonist is used? Give two reasons for including the antagonist in the formulation.**

<Expander title="Reveal suggested answer...">
 <p>
  <strong>
   Suggested answer
  </strong>
 </p>
 <p>
  Naloxone is combined with buprenorphine and with oxycodone. Naloxone is poorly absorbed from the gastrointestinal tract.
 </p>
 <p>
  In buprenorphine–naloxone sublingual tablets, the antagonist is included to deter misuse by injection because naloxone can provoke unpleasant withdrawal symptoms in opioid-dependent individuals.
 </p>
 <p>
  In the combination with oxycodone, naloxone is an antagonist at opioid receptors in the gastrointestinal tract—it reduces opioid-induced effects on the bowel.
 </p>
</Expander>







[^1]: A substance that binds to a receptor but produces no effect and inhibits an agonist from binding to the receptor
